Navigation Links
Tengion Provides Business Update and Reports Second Quarter 2011 Financial Results
Date:8/9/2011

EAST NORRITON, Pa., Aug. 9, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today provided a business update and reported its financial results for the second quarter ended June 30, 2011.

"This is an important time for Tengion as we continue to make progress on our lead clinical and preclinical programs, as well as on our corporate and partnership strategy," said David Scheer, chairman of the Tengion board of directors. "Our search for a new chief executive officer is underway and our dialogue with the FDA is ongoing as we continue to advance our Neo-Urinary Conduit clinical trial. We expect to provide more updates in the near term as we execute on our overall strategy."

Neo-Urinary Conduit Bladder Cancer Trial – Clinical UpdateTengion is currently conducting an initial clinical trial of its lead product candidate, the Neo-Urinary Conduit™, for use in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy).  The Neo-Urinary Conduit is a combination of a patient's own cells and bioabsorbable scaffold that is intended to catalyze regeneration of a native bladder tissue conduit, passively transporting urine from the ureters through a stoma, or hole in the abdomen, into a standard ostomy bag.  Patients requiring some form of urinary diversion with today's standard of care, the use of a segment of bowel tissue to construct a conduit for urine to exit from the body into an ostomy bag, are at risk of complications associated with the use of bowel tissue as well as those associated with the surgery to harvest the bowel tissue.

The trial is designed to assess the safety and preliminary efficacy of the Neo-Urinary Conduit, as well as to allow the clinical investigators to optimize the surgical procedure and post-surgical care by incorporating the outcomes observed in each patient into the surgical approach f
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tengion Announces Leadership Transition
2. Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
3. Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2011 Financial Results on May 12, 2011
4. Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel
5. Tengion To Host Conference Call To Provide a Business Update and Report Fourth Quarter 2010 Financial Results on March 25, 2011
6. Tengion Announces Pricing of $31.4 Million Private Placement
7. Tengion Addresses Recent Trading Activity in its Common Stock
8. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
9. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
10. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
11. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 During the ... now known as “The Doctor’s Plague.” In this time period, ... hands. This led, at times, to the death of vulnerable ... today don’t know that they may be unwittingly transmitting herpes ...
(Date:1/14/2014)... MO (PRWEB) January 14, 2014 Holloway ... comprehensive database of material test reports (MTRs) for all ... fabricates. Documenting test results is particularly important for equipment ... regulations. The MTR Library features search functionality that allows ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... Va., April 10 Insmed Inc. (Nasdaq:,INSM), a ... of a letter and questionnaire from the Chairman ... Subcommittee on Health,on the possible development of legislation ... Sent to approximately 30 stakeholders in the biotechnology ...
... ATS 3f Valve, MINNEAPOLIS, April 10 ... marketer of state-of-the-art cardiac,surgery products and services, today ... ATS 3f(R) Aortic Bioprosthesis. Canadian,regulatory approval was received ... was performed by Benoit de Varennes, MD, MSc, ...
... Vision of Becoming a Global Leader in ... ... Mass., April 10 ,Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and ... entered,into a definitive agreement pursuant to which Takeda will acquire,Millennium for ...
Cached Biology Technology:Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 2Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 3ATS Medical Announces First North American Commercial Implant of the ATS 3f Aortic Bioprosthesis 2ATS Medical Announces First North American Commercial Implant of the ATS 3f Aortic Bioprosthesis 3Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 2Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 3Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 4Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 5Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 6Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 7
(Date:4/17/2014)... Kansas State University engineer has developed a patented ... improvised explosive devices. The same technique could help ... Steven M. and Kay L. Theede chair in ... engineering, and his research team have created a ... in car trunks. The distance detection method ...
(Date:4/17/2014)... RIVERSIDE, Calif. One day about eight years ago, ... of California, Riverside, and her father were on a field ... stumbled upon an orchid they had never seen before. , ... authority on orchids. The orchid turned out to be ... Silveras: Lophiaris silverarum . , "Lophiaris" is the genus ...
(Date:4/17/2014)... release is available in German . ... pay the protection money demanded of him, he can expect ... required, however, as fear of the consequences is enough to ... in parasitic birds, which lay their eggs in other birds, ... the brood parasites take their revenge by destroying the entire ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... too much growth in patients has now also been ... can lead to very different conditions, according to research ... IMAGe* syndrome is a rare developmental disorder which ... body and organ size. Without treatment, the disorder can ...
... climate change because they don,t understand the science behind ... more proficient in technical reasoning, would public consensus match ... the journal Nature Climate Change suggests that ... members of the public become more science literate and ...
... see how a common house sparrow and a Tyrannosaurus Rex might ... weighs less than an ounce, and the other is a dinosaur ... scales at more than eight tons. For all their ... than many believed. A new study, led by Harvard scientists, has ...
Cached Biology News:Variations of a single gene can lead to too much or too little growth, study shows 2Yale study concludes public apathy over climate change unrelated to science literacy 2Timing is everything 2Timing is everything 3Timing is everything 4
The Wellwash 4 Mk 2 microplate washer combines flexibility, simplicity and ease of use. This reliable microplate washer meets the exacting standards of today's ELISA assay requirements....
... genetically engineered endonuclease. This unique enzyme degrades ... having no proteolytic activity. It is effective ... possesses an exceptionally high specific activity. Ideal ... proteins, its use enables compliance with FDA ...
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Rice microRNA Microarray contains ...
... selects single cells, or clusters, with rapid, ... all, a single cell can be targeted, ... collected into the pipette, and automatically transferred ... plate. Quixells unique aspiration and expulsion system ...
Biology Products: